Elevated glucocorticoid (GC) activity may limit tumor immune response and immune
checkpoint inhibitor (ICI) efficacy. Adrenocortical carcinoma (ACC) provides a unique test …

Background Adrenocortical carcinoma (ACC) is a rare and highly aggressive endocrine
malignancy, of which> 40% present with glucocorticoid excess. Glucocorticoids and …

Despite progress in understanding the biology of adrenocortical carcinoma (ACC), treatment
options have not dramatically changed in the last three decades, nor have we learned how …

Adrenocortical carcinoma (ACC) is a rare but highly aggressive malignancy. Nearly half of
ACC tumours overproduce and secrete adrenal steroids. Excess cortisol secretion, in …

Adrenocortical carcinoma (ACC) is a rare endocrine tumor, and most cases present with
hormone excess with poor prognosis. Our research aims to determine the clinical and …

e16617 Background: ACC is a rare and aggressive malignancy. Response rates to ICI are
low with scarce yet promising durable responses. Molecular ACC subtypes have been …

Background Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Even with
complete tumor resection and adjuvant therapies, the prognosis of patients with ACC …

Background Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Tumor-related
glucocorticoid excess is present in~ 60% of patients and associated with particularly poor …

Purpose: Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with few
therapies; however, patients with locoregional disease have variable outcomes. The Cancer …

Adrenocortical carcinoma (ACC) is a rare yet devastating tumour of the adrenal gland with a
molecular pathology that remains incompletely understood. To gain novel insights into the …